Publications by authors named "Sarah Rochestie"
Article Synopsis
- PD-1 inhibitors show limited effectiveness on their own for treating hepatocellular carcinoma (HCC), but a new personalized therapeutic cancer vaccine (PTCV) may boost their efficacy by enhancing immune responses against tumors.
- In a study, a DNA plasmid PTCV combined with pembrolizumab was tested on patients with advanced HCC; the treatment was found to be relatively safe with manageable side effects and showed a 30.6% objective response rate.
- The study observed that patients with more neoantigens from the vaccine had better clinical responses, with immune profiling revealing a strong T cell response directed at tumor cells, supporting the vaccine's potential as a viable therapeutic approach.
